Clinical Trial

Effect of Finerenone in IgA Nephropathy

Study acronym: FIGHT
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2024 (before its estimated June 8, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients with IgA nephropathy. The primary endpoint event was the change in urinary albumin/creatinine ratio between the two groups at 12 months of treatment.
Trial Details
NCT Number NCT06580288
Lead Sponsor Zhejiang University
Conditions IgA Nephropathy
Enrollment 120 participants
Start Date 2024-10-08
Primary Completion 2026-06-08 (estimated)
Study Completion 2026-10-08 (estimated)
Updated on ClinicalTrials.gov 2024-08-30